Related Experiment Videos
Drug treatment associated with heart valve replacement
D S Coulshed1, M A Fitzpatrick, C H Lee
1Department of Cardiology, Nepean Hospital, Penrith, New South Wales, Australia.
Insights
Patients with mechanical heart valves require anticoagulation, with International Normalized Ratio (INR) targets potentially adjustable based on bleeding risk. High-risk patients may benefit from aspirin, and specific management is advised for pregnancy and surgery.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Prosthetic heart valves necessitate careful pharmacological management to prevent complications.
- Anticoagulation strategies have evolved, with ongoing research into optimal International Normalized Ratio (INR) targets.
Purpose of the Study:
- To review pharmacological considerations for patients with prosthetic heart valves.
- To discuss anticoagulation, antiplatelet therapy, and antibiotic prophylaxis in this patient population.
Main Methods:
- Review of current literature and clinical guidelines.
- Analysis of pharmacological recommendations based on valve type, patient risk factors, and clinical scenarios.
Main Results:
- Mechanical heart valves generally require anticoagulation, with potential for lower INR targets (1.8-3.5) in low-risk patients.
- High-risk patients may require aspirin in addition to anticoagulation.
- Specific management protocols exist for pregnancy, non-cardiac surgery, and acute valve thrombosis.
- Antibiotic prophylaxis is recommended for invasive procedures to prevent endocarditis.
Conclusions:
- Pharmacological management for prosthetic heart valves is individualized based on valve type, thromboembolic risk, and bleeding risk.
- Current evidence suggests a potential shift towards individualized INR targets.
- Proactive management, including prophylaxis, is crucial for optimizing outcomes.
Abstract:
This article reviews a number of specific pharmacological considerations for patients with prosthetic heart valves. All patients with mechanical heart valves should be anticoagulated. In the past, an International Normalised Ratio (INR) of 2.5 to 4.5 has been recommended. Recent nonrandomised studies have suggested that a patient with a prosthetic valve who is at low risk for thromboembolic events could have an INR ranging from 1.8 to 3.5. The lower end of this range should only be used for patients at higher than average risk of haemorrhage, until randomised data show that levels below 2.5 may be applied universally. In high-risk patients (particularly those with previous thromboembolic events) low dose aspirin should be added. During noncardiac surgery, a patient at low risk for thromboembolic events could be managed by discontinuing anticoagulation 3 days before the operation, with warfarin recommenced as soon as possible afterwards. Perioperative heparinisation would be appropriate in a higher risk patient. Women with prosthetic heart valves wishing to become pregnant should be converted to the use of twice-daily subcutaneous heparin injections. Patients with bioprosthetic valves can be managed without anticoagulation unless they have some other reason to require it. Patients at high risk should be treated with aspirin or warfarin. Thrombolytic therapy for acute valve thrombosis should be used for those who are haemodynamically compromised and therefore have a high risk of mortality from operative intervention. All patients with prosthetic heart valves undergoing invasive procedures potentially causing bacteraemia should receive antibiotic prophylaxis for endocarditis. The actual drugs used depend on the likely nature of the bacteraemia, and any possible patient hypersensitivity.